Adnan Mjalli, TransTech Pharma
S
Adnan Mjalli
Co-founder, President, CEO, TransTech Pharma
BORN: On the West Bank, Jerusalem, to farmers
BIGGEST ACCOMPLISHMENT: Key discoveries in Alzheimer's and diabetes
People can manufacture cars, computers, everything, faster and cheaper," says Adnan Mjalli. "Everything around us has become more portable and available, except for medicine. It's embarrassing how Big Pharma has become an old, rusty environment for drug discovery."
Adnan Mjalli
The argument would be easier to dismiss if he wasn't such a prolific scientist. But with more than 620 patents under his belt and a slew of INDs, Mjalli underscores his point with the success of the company he founded, TransTech Pharma.
Mjalli says the engine of the success is his proprietary translational technology platform, which was used to discover all of the company's portfolio drugs. The platform's effectiveness has led the company to strike deals with a major pharma for each of the last seven years.
Mjalli received much of his training as a scientist while working at Merck, but marries those skills with a natural bent for business. "I've always had good judgment on which scientific area would lead to a breakthrough," he says. "We're seeing more scientists coming out of the lab to understand the business, like the scientists who head Vertex and Cephalon. They do a much better job than a pure CEO of connecting the business to the work that goes on every day."
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
April 14th 2025LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
